Quantcast

Latest Angiogenesis Stories

2011-08-11 12:08:26

Thomas Jefferson University research suggests a potential target"”Angiotensin II type 2 receptor"”for chemopreventive agents to fight pancreatic cancer Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division. With that, a new...

2011-08-10 06:45:25

(Ivanhoe Newswire)--Researchers are gaining insight on how to slow the growth of tumors via angiogenesis inhibitors. Angiogenesis is the process involving the growth of new blood vessels from pre-existing ones. This is a normal process for growth and development as well as wound healing. Angiogenesis has also been proven to be a fundamental step in transitioning tumors from a dormant state to a malignant one which leads to the use of inhibitors which eliminate blood supply to these tumors....

2011-08-08 06:45:41

Shows promise for development of anti-tumor drugs Researchers have gained a new understanding of the way in which growing tumors are fed and how this growth can be slowed via angiogenesis inhibitors that eliminate the blood supply to tumors. This represents a step forward towards developing new anti-cancer drug therapies. The results of this study have been published today in the September issue of The American Journal of Pathology. "The central role of capillary sprouting in tumor...

2011-08-04 08:00:00

FORT WORTH, Texas, Aug. 4, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced positive topline results for its Phase IIb clinical trial investigating the efficacy of HP802-247 in venous leg ulcers. HP802-247 is an investigational allogeneic living cell suspension containing keratinocytes and fibroblasts. The study was designed to determine the potential effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care,...

2011-07-20 17:23:02

Melanoma is devastating on many fronts: rates are rising dramatically among young people, it is deadly if not caught early, and from a biological standpoint, the disease tends to adapt to even the most modern therapies, known as VEGF inhibitors. University of Rochester researchers, however, made an important discovery about proteins that underlie and stimulate the disease, opening the door for a more targeted treatment in the future. This month in the journal Cancer Research, Lei Xu, Ph.D.,...

2011-07-07 19:25:41

Scientists at the University of Southampton have developed smart nanomaterials, which can disrupt the blood supply to cancerous tumors. The team of researchers, led by Physics lecturer Dr Antonios Kanaras, showed that a small dose of gold nanoparticles can activate or inhibit genes that are involved in angiogenesis - a complex process responsible for the supply of oxygen and nutrients to most types of cancer. "The peptide-functionalized gold nanoparticles that we synthesized are very...

2011-07-02 02:29:20

Natural plant compound blocks vessel growth by interfering with cellular adhesion Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs "“ agents that interfere with the development of blood vessels. In a report in Proceedings of the National Academy of Sciences/Early Edition, the investigators describe how a compound derived from a South American tree was able, through a novel mechanism, to interfere with blood...

2011-06-23 07:30:00

BARCELONA, Spain, June 23, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented pre-clinical research results at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor...

2011-06-22 08:00:00

SAN DIEGO, June 22, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced the selection of the Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory (Cedars-Sinai Core Laboratory), Los Angeles, California, to serve as the central core lab for the Company's Generx ASPIRE clinical study. Cedars-Sinai Core Laboratory will be responsible for the consolidation and analysis of SPECT (single-photon emission computed tomography) myocardial imaging data from the...

2011-06-17 06:05:00

TARRYTOWN, N.Y., June 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that NASDAQ has halted trading of the company's common stock today. The Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is meeting today to discuss the company's Biologics License Application (BLA) for EYLEA(TM), also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD)....


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related